EMG
PTCT icon

Ellington Management Group’s PTC Therapeutics PTCT Stock Holding History

Ellington Management Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-17,600
Closed -$827K – 567
2018
Q3 		$827K Buy
+17,600
New +$728K 0.22% 122
2015
Q3 		– Sell
-10,400
Closed -$501K – 858
2015
Q2 		$501K Buy
+10,400
New +$607K 0.12% 238

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Ellington Management Group's PTCT Position: Q4 2018 in Review

Ellington Management Group sold out of PTC Therapeutics (PTCT) in Q4 2018, closing a stake of 17,600 shares — an estimated $827K sold.

Ellington Management Group first reported a position in PTCT in Q2 2015 and held it in 2 quarters. The position peaked at $827K in Q3 2018. 164 funds tracked by Wall St. Rank hold PTCT as of Q4 2018.

  • Ellington Management Group reported no remaining PTC Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Ellington Management Group sold 17,600 PTC Therapeutics shares in Q4 2018, an estimated $827K.
  • Ellington Management Group first reported a position in PTC Therapeutics in Q2 2015 and held it in 2 quarters.
  • Ellington Management Group's PTC Therapeutics position peaked at $827K in Q3 2018.
  • 164 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2018.

Based on Ellington Management Group's 13F filing for Q4 2018, filed 14 Feb 2019.